trial · primary record
Pembrolizumab
Malignant Neoplasm of Breast
| Phase | Phase 1 |
|---|---|
| Status | COMPLETED |
| Sponsor | Unknown |
| Enrolment | 18 |
| Primary completion | 2026-10-30 |
| Primary endpoint | Maximum Tolerated Dose (MTD) of Intratumoral Injection of Clostridium Novyi-NT with Pembrolizumab |
| Registry ID | NCT03435952 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:11.747Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT03435952
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Pembrolizumab · approval
- Pembrolizumab · compound